The WATCHMAN device for stroke prophylaxis in atrial fibrillation: an evolving niche

References

• Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–53
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–8
   PubMed Web of Science ®Google Scholar
• Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049–56
   PubMed Web of Science ®Google Scholar
• Tu HT, Campbell BC, Christensen S, et al. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2010;30:389–95
   PubMed Web of Science ®Google Scholar
• Blackshear JL, Safford RE; AFFIRM trial; RACE trial. AFFIRM and RACE trials: implications for the management of atrial fibrillation. Cardiac Electrophysiol Rev 2003;7:366–9
   PubMedGoogle Scholar
• DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:650–6
   PubMed Web of Science ®Google Scholar
• Sabir IN, Matthews GD, Huang CL. Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice. Postgrad Med J 2013;89:346–51
   Google Scholar
• European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–420
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67
   PubMed Web of Science ®Google Scholar
• Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med 2012;172:623–31; discussion 631–623
   PubMedGoogle Scholar
• Ferro D, Loffredo L, Polimeni L, Violi F. Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2007;2:24–8
   Google Scholar
• Lam YY, Ma TK, Yan BP. Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation. Int J Cardiol 2011;150:4–11
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lip GY, Apostolakis S. New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart 2012;98:1341–7
   PubMed Web of Science ®Google Scholar
• Harris K, Mant J. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. Int J Clin Pract 2013;67:647–55
   Google Scholar
• Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755–9
   PubMed Web of Science ®Google Scholar
• Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999;82:547–54
   PubMedGoogle Scholar
• Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal echocardiography. Implications for the development of thrombus. Circulation 1991;84:223–31
   PubMed Web of Science ®Google Scholar
• Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol 2013;61:1790–8
   Google Scholar
• Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 2013;127:720–9
   PubMed Web of Science ®Google Scholar
• Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology (ASAP study). J Am Coll Cardiol 2013;61:2551–6
   PubMed Web of Science ®Google Scholar
• Holmes DRJr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1–12
   PubMed Web of Science ®Google Scholar
• Holmes DRJr, Lakkireddy DR, Whitlock RP, Waksman R, Mack MJ. Left atrial appendage occlusion: opportunities and challenges. J Am Coll Cardiol 2014;63:291–8
   Google Scholar
• Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interact Cardiovasc Thorac Surg 2010;10:306–11
   PubMed Web of Science ®Google Scholar
• Madden JL. Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. JAMA 1949;140:769–72
   PubMed Web of Science ®Google Scholar
• Apostolakis E, Papakonstantinou NA, Baikoussis NG, Koniari I, Papadopoulos G. Surgical strategies and devices for surgical exclusion of the left atrial appendage: a word of caution. J Cardiac Surg 2013;28:199–206
   Google Scholar
• Landmesser U, Holmes DRJr. Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 2012;33:698–704
   Google Scholar
• Khattab AA, Meier B. Transcatheter left atrial appendage closure for stroke prevention among atrial fibrillation patients. Expert Review Cardiovasc Ther 2012;10:819–21
   Google Scholar
• Luis SA, Roper D, Incani A, Poon K, Haqqani H, Walters DL. Non-pharmacological therapy for atrial fibrillation: managing the left atrial appendage. Cardiol Res Pract 2012;2012:304626
   Google Scholar
• Freixa X, Chan JL, Tzikas A, Garceau P, Basmadjian A, Ibrahim R. The Amplatzer Cardiac Plug 2 for left atrial appendage occlusion: novel features and first-in-man experience. EuroIntervention 2013;8:1094–8
   Web of Science ®Google Scholar
• Gangireddy SR, Halperin JL, Fuster V, Reddy VY. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J 2012;33:2700–8
   Web of Science ®Google Scholar
• Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013;62:108–18
   PubMed Web of Science ®Google Scholar
• Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417–24
   PubMed Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534–42
   PubMed Web of Science ®Google Scholar
• Guerios EE, Schmid M, Gloekler S, et al. Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation. Arq Bras Cardiol 2012;98:528–36
   Web of Science ®Google Scholar
• Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011;77:700–6
   PubMed Web of Science ®Google Scholar
• Bayard YL, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 2010;6:220–6
   Web of Science ®Google Scholar
• Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005;46:9–14
   PubMed Web of Science ®Google Scholar
• Bayard YL, Ostermayer SH, Sievert H. Transcatheter occlusion of the left atrial appendage for stroke prevention. Expert Rev Cardiovasc Ther 2005;3:1003–8
   PubMedGoogle Scholar
• Freixa X, Abualsaud A, Chan J, et al. Left atrial appendage occlusion: initial experience with the Amplatzer Amulet. Int J Cardiol 2014;174:492–6
   Web of Science ®Google Scholar
• Lam SC, Bertog S, Gafoor S, et al. Left atrial appendage closure using the amulet device: An initial experience with the second generation amplatzer cardiac plug. Catheter Cardiovasc Interv 2014;10.1002/ccd.25644
   Google Scholar
• Stone D, Byrne T, Pershad A. Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation. 2013;Catheter Cardiovasc Interv 10.1002/ccd.25065
   Google Scholar
• Sakellaridis T, Argiriou M, Charitos C, et al. Left atrial appendage exclusion—where do we stand? J Thorac Dis 2014;6:S70–7
   Google Scholar
• Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006;151:956–61
   PubMed Web of Science ®Google Scholar
• Bergmann MW, Landmesser U. Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques. EuroIntervention 2014;10:497–504
   PubMed Web of Science ®Google Scholar
• Singh SM, Douglas PS, Reddy VY. The incidence and long-term clinical outcome of iatrogenic atrial septal defects secondary to transseptal catheterization with a 12F transseptal sheath. Circ Arrhythm Electrophysiol 2011;4:166–71
   Google Scholar
• Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012;59:923–9
   PubMed Web of Science ®Google Scholar
• PREVAIL published: Watchman safe, meets one of two efficacy end points. http://www.medscape.com/viewarticle/827567. Accessed August 8, 2014
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92
   PubMed Web of Science ®Google Scholar
• Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL). http://clinicaltrials.gov/show/NCT01182441. Accessed October 6, 2013
   Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62
   PubMed Web of Science ®Google Scholar
• Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 2010;10:125–41
   PubMed Web of Science ®Google Scholar
• Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007;49:1490–5
   PubMed Web of Science ®Google Scholar
• Fairbairn TA, Meads DM, Mather AN, et al. Serial change in health-related quality of life over 1 year after transcatheter aortic valve implantation: predictors of health outcomes. J Am Coll Cardiol 2012;59:1672–80
   PubMed Web of Science ®Google Scholar
• Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005;150:288–93
   PubMedGoogle Scholar
• Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013;34:1498–505
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104
   PubMed Web of Science ®Google Scholar
• Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. Br J Surg 2014;101:742–9
   PubMed Web of Science ®Google Scholar
• Lauw MN, Coppens M, Eikelboom JW. Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent. Can J Cardiol 2014;30:381–4
   Google Scholar
• Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost 2014;40:756–65
   Google Scholar
• Lip GY, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 2014;35:1844–55
   PubMed Web of Science ®Google Scholar
• Frost C, Shenker A, Gandhi MD, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol 2014;78:877–85
   PubMed Web of Science ®Google Scholar
• Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother 2014;48:734–40
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395–401
   PubMed Web of Science ®Google Scholar
• Lewalter T, Ibrahim R, Albers B, Camm AJ. An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Europace 2013;15:652–6
   PubMed Web of Science ®Google Scholar
• Viles-Gonzalez JF, Reddy VY, Petru J, et al. Incomplete occlusion of the left atrial appendage with the percutaneous left atrial appendage transcatheter occlusion device is not associated with increased risk of stroke. J Interv Cardiac Electrophysiol 2012;33:69–75
   Google Scholar
• Schwartz RS, Holmes DR, Van Tassel RA, et al. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. JACC Cardiovasc Interv 2010;3:870–7
   PubMed Web of Science ®Google Scholar
• Lam SC, Bertog S, Sievert H. Incomplete left atrial appendage occlusion and thrombus formation after Watchman implantation treated with anticoagulation followed by further transcatheter closure with a second-generation Amplatzer Cardiac Plug (Amulet device). Catheter Cardiovasc Interv 2014;10.1002/ccd.25456
   Google Scholar